Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dutch biotech firm Crucell has signed two cardiovascular disease-related licensing agreements with Korean biopharmaceutical company BIOA&D.
Subscribe to our email newsletter
The first agreement relates to the use of Crucell's PER.C6 technology in the production of adenoviral vectors expressing ceNOS (constituted endothelial nitric oxide synthase) for the treatment of cardiovascular disease.
Several Crucell products are based on its unique PER.C6 production technology. The company licenses this and other technologies to the biopharmaceutical industry, with important partners and licensees including Sanofi-Aventis, GlaxoSmithKline and Merck & Co.
In addition to the PER.C6 deal, Crucell and BIOA&D have signed an agreement that allows the Koran firm to use Crucell's patented ceNOS gene therapy technology.
ceNOS is an enzyme that produces nitric oxide, a molecule known to be beneficial in various applications for cardiovascular disease. Crucell developed intellectual property related to ceNOS in the late 1990s when the company was engaged in a gene therapy research program.
Under the terms of the license agreements, BIOA&D will pay a signing fee, annual maintenance fees and milestone payments upon commercialization. Further financial details were not disclosed.